GLP-1 Medications and Eating Disorders: What You Should Know

These days, it’s nearly impossible to scroll through social media or turn on your TV without seeing ads for GLP-1 medications like Ozempic, Wegovy, and Mounjaro. Originally developed for Type 2 diabetes, these medications are now aggressively marketed for weight loss.

But behind their rising popularity lies a more complicated reality—one that raises concerns for those at risk of or recovering from eating disorders. Appetite suppression and rapid weight loss can reinforce disordered behaviors, disrupt recovery, and validate harmful cultural messages about body size and self-worth.

What’s more, many people with eating disorders—particularly those in larger bodies—remain undiagnosed, making them especially vulnerable to these unintended risks. When weight loss is framed as a universal good, it can overshadow the real complexities of health and well-being.

This blog explores the intersection of GLP-1 medications and eating disorders, examining their risks, cultural implications, and the need for a more compassionate, inclusive approach to health and healing.

What Are GLP-1 Medications and How Do They Work?

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications originally developed to treat Type 2 diabetes. These drugs mimic GLP-1, a natural hormone that helps regulate blood sugar and appetite after eating.

GLP-1 medications work by:

• Enhancing insulin production: Stimulates the pancreas to produce more insulin when blood sugar levels are high

• Reducing glucagon release: Decreases the secretion of glucagon, a hormone that raises blood sugar

• Delaying gastric emptying: Slows the speed of food leaving the stomach, modulating blood sugar and extending feelings of fullness

• Impacts hunger pathways: Interacts with brain receptors to influence hunger and fullness cues, reducing cravings and promoting satiety

Beyond Diabetes Management

Shortly after their introduction, researchers observed that GLP-1s often led to weight loss. In 2021, the FDA approved semaglutide (Wegovy) for chronic weight management in specific medical contexts.

For individuals managing diabetes and related conditions, these drugs can be life-changing. But as their use expands beyond medical necessity into weight-loss treatments for populations without diabetes, concerns arise. How do these medications interact with eating behaviors? And what are the risks when they’re introduced into a culture already obsessed with the pursuit of thinness? To fully understand these risks, we must first examine how diet culture and weight stigma influence our perceptions of health and body size.

How Diet Culture and Weight Stigma Fuel Eating Disorders

Eating disorders don’t develop in a vacuum. While biological and psychological factors may predispose someone to an eating disorder, societal pressures—particularly diet culture and weight stigma—often act as powerful triggers. These forces shape how we think about bodies, food, and self-worth, influencing everything from personal choices to public health policies and medical treatments.

The Role of Diet Culture

Diet culture teaches that thinness and leanness equals health, success, and worth, framing weight loss as a universal goal. It moralizes food choices (e.g., labeling foods as “good” or “bad”), instills fear of weight gain, and prioritizes appearance over true well-being.

These messages are deeply embedded in daily life:

• Social Media: Idealized body types and weight-loss trends dominate feeds, fueling comparison and pressure to conform.

• The Wellness Industry: Dieting has been rebranded as “clean eating,” “detoxing,” or “lifestyle changes”—often disguising restrictive habits as self-care. Many wellness trends claim that “health” is about discipline, control, and avoiding certain foods, embedding diet culture into everyday choices.

• Public Health Narratives: While some initiatives promote holistic well-being, others frame weight as the defining marker of health, reinforcing the harmful idea that thinness is inherently better.

Diet culture affects everyone, contributing to body dissatisfaction, disordered eating behaviors, and weight stigma. For those at risk for or recovering from eating disorders, these messages don’t just add pressure—they validate disordered thoughts, making recovery even harder.

GLP-1 medications don’t exist in isolation—they reflect and reinforce diet culture’s harmful ideals, positioning appetite suppression and weight loss as medical “solutions.” But the damage doesn’t stop there. While diet culture promotes thinness as an ideal, weight stigma punishes those who don’t conform.

The Role of Weight Stigma

Diet culture creates the conditions for disordered eating, while weight stigma reinforces them. Weight stigma refers to discrimination, bias, or negative attitudes directed toward people based on body size.

Not only does weight stigma contribute to body dissatisfaction, anxiety, and depression, it also shapes healthcare, medical treatments, and access to support—including how GLP-1s are prescribed and discussed.

Here are three key ways it appears:

• Healthcare Disparities: Too often, people in larger bodies receive inadequate medical care, as providers may overlook symptoms or attribute all health concerns to weight rather than investigating underlying issues. This can lead to misdiagnosis, delayed treatment, and missed eating disorder diagnoses—especially for individuals with atypical anorexia or binge eating disorder, conditions frequently dismissed due to weight bias.

• Social & Workplace Bias: Studies show that individuals in larger bodies experience discrimination in hiring, promotions, and wages, reinforcing harmful ideas that body size determines competence or success.

• Internalized Weight Stigma: Frequent exposure to weight stigma increases body dissatisfaction, anxiety, and depression—all risk factors for developing or worsening an eating disorder. When people internalize these beliefs, they may feel unworthy of care, struggle to embrace recovery, or resort to disordered behaviors as a coping mechanism.

Because weight bias often delays eating disorder diagnoses, it’s essential that individuals are thoroughly screened for disordered eating behaviors before being prescribed GLP-1 medications. Eating disorders affect people of all sizes, yet many—especially those in larger bodies—struggle for years before receiving an accurate diagnosis. This underscores the need for healthcare providers to look beyond BMI and consider the full picture of a patient’s relationship with food, weight, and body image before treatment recommendations.

By positioning appetite suppression and weight loss as medical “solutions,” GLP-1s reinforce weight stigma—treating body size as a problem rather than acknowledging the complexity of health. But weight stigma doesn’t just harm individuals—it actively creates the conditions that lead to eating disorders in the first place.

The solution isn’t prescribing around weight stigma—it’s challenging it.

How GLP-1 Medications Affect Eating Disorder Recovery

Eating disorder recovery relies on rebuilding trust in the body’s natural cues, developing consistent eating patterns, and shifting focus away from weight control. But GLP-1 medications—by suppressing appetite and promoting weight loss—can complicate these essential aspects of healing.

How GLP-1s Disrupt Eating Behaviors

GLP-1 medications interfere with recovery in several ways:

• Blurring Hunger Signals: Appetite suppression makes it harder to recognize and respond to the body’s natural hunger signals—a critical step in recovery. For those relearning how to eat consistently, this creates additional challenges.

• Reinforcing Restrictive Patterns: The prolonged fullness caused by GLP-1s can unintentionally validate harmful thoughts about skipping meals, eating too little, or ignoring hunger cues.

• Disrupting Meal Structure: Side effects like nausea and prolonged fullness can make structured eating—an essential part of recovery—more difficult to maintain.

GLP-1s and Specific Eating Disorder Risks

The impact of GLP-1s varies across different eating disorder diagnoses:

• Restrictive Eating (e.g., anorexia nervosa, atypical anorexia nervosa): Appetite suppression and weight loss increase the risk of malnutrition, dangerous electrolyte imbalances, and potentially life-threatening complications like refeeding syndrome.

• Binge Eating (e.g., binge eating disorder, bulimia nervosa): While GLP-1s may temporarily reduce binge episodes due to appetite suppression, they do not address the underlying emotional or psychological triggers. In fact, appetite suppression can worsen the binge-restrict cycle, reinforcing disordered patterns.

• Purging Behaviors (e.g., bulimia nervosa): By slowing stomach emptying, GLP-1s often cause nausea and stomach pain. This may lead individuals to increase purging behaviors like vomiting or laxative misuse in an effort to relieve discomfort.

Holistic Care for Lasting Recovery

At The Emily Program, we understand that true recovery is not about control—it’s about reclaiming trust in your body and healing your relationship with food. Our weight-inclusive, individualized care challenges the cultural narratives that tie self-worth to body size, empowering individuals to find lasting freedom from disordered eating.

Our holistic approach to eating disorder treatment prioritizes:

• Rebuilding Trust in the Body: Relearning how to listen to and honor hunger and fullness cues without guilt or external pressure

• Nurturing Self-Compassion: Breaking free from diet culture’s harmful messages and embracing body respect, not shame

• Strengthening Emotional Resilience: Developing coping skills that support long-term healing—without relying on disordered behaviors like restriction or appetite suppression

Healing is possible, and you don’t have to do it alone.

If you or someone you love is struggling with an eating disorder—or feeling unsure about GLP-1 medications—our team is here to help. Reach out today by completing our online form or calling us at 1-888-364-5977 to take the first step toward healing.

Want to Learn More? Watch Our Free, On-Demand Webinar on GLP-1s and Eating Disorders

For a deeper dive into the growing use of GLP-1 medications and their impact on eating disorders, watch our self-paced, pre-recorded webinar: OMG[LP-1s] – Eating Disorders and the Rise of Glucagon-Like Peptide-1 Receptor Agonists, led by experts Stacy Schilter Pisano, LMFT, CEDS-S and M. Hilmar Wagner, MPH, RDN, LN, CD.